MARKET

OBIO

OBIO

Orchestra BioMed Holdings Inc
NASDAQ
2.720
-0.010
-0.37%
After Hours: 2.720 0 0.00% 16:04 05/23 EDT
OPEN
2.670
PREV CLOSE
2.730
HIGH
2.750
LOW
2.605
VOLUME
111.84K
TURNOVER
--
52 WEEK HIGH
8.87
52 WEEK LOW
2.370
MARKET CAP
104.21M
P/E (TTM)
-1.5356
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OBIO last week (0512-0516)?
Weekly Report · 4d ago
Promising Innovations and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings
TipRanks · 05/16 16:15
Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism
Seeking Alpha · 05/14 04:45
Orchestra BioMed Holdings Price Target Maintained With a $20.00/Share by Chardan Capital
Dow Jones · 05/13 22:22
Orchestra BioMed Holdings Is Maintained at Buy by Chardan Capital
Dow Jones · 05/13 22:22
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Benzinga · 05/13 22:12
Orchestra BioMed GAAP EPS of -$0.49, revenue of $0.9M
Seeking Alpha · 05/13 13:13
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/12 21:40
More
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Webull offers Orchestra Biomed Holdings Inc stock information, including NASDAQ: OBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OBIO stock methods without spending real money on the virtual paper trading platform.